Priority Review to Merck for KEYTRUDA Plus Chemo for Locally Advanced Cervical Cancer

 Acceptance based on results from the Phase 3 KEYNOTE-A18 trial, which showed a statistically significant and clinically meaningful improvement in progression-free survival in these patients

https://www.biospace.com/article/releases/fda-grants-priority-review-to-merck-s-application-for-keytruda-pembrolizumab-plus-concurrent-chemoradiotherapy-as-treatment-for-patients-with-newly-diagnosed-high-risk-locally-advanced-cervical-cancer/